Frederick W Wackerle Net Worth

The estimated Net Worth of Frederick W Wackerle is at least $535 Tysiąc dollars as of 17 November 2005. Frederick Wackerle owns over 10,000 units of Immutep stock worth over $313,877 and over the last 21 years Frederick sold IMMP stock worth over $220,920.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Frederick Wackerle IMMP stock SEC Form 4 insiders trading

Frederick has made over 2 trades of the Immutep stock since 2003, according to the Form 4 filled with the SEC. Most recently Frederick bought 10,000 units of IMMP stock worth $65,800 on 17 November 2005.

The largest trade Frederick's ever made was selling 12,000 units of Immutep stock on 17 September 2003 worth over $220,920. On average, Frederick trades about 2,444 units every 88 days since 2003. As of 17 November 2005 Frederick still owns at least 121,188 units of Immutep stock.

You can see the complete history of Frederick Wackerle stock trades at the bottom of the page.

What's Frederick Wackerle's mailing address?

Frederick's mailing address filed with the SEC is 3750 N Lake Shore Dr, Chicago, IL 60613, USA.

Insiders trading at Immutep

Over the last 21 years, insiders at Immutep have traded over $3,152,820 worth of Immutep stock and bought 15,000 units worth $128,330 . The most active insiders traders include Kon Fung Chan, Frederick W Wackerle oraz Levi Hong Kaye Lee. On average, Immutep executives and independent directors trade stock every 132 days with the average trade being worth of $138,215. The most recent stock trade was executed by Frederick W Wackerle on 17 November 2005, trading 10,000 units of IMMP stock currently worth $65,800.

What does Immutep do?

immutep is a globally active biotechnology company, listed on the australian stock exchange and on the nasdaq global market in the us. as a leader in personalized bio-therapeutic products for cancer, immutep is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. immutep's main pipeline of products is based on the lag-3 immune control mechanism which plays a vital role in the regulation of the t cell immune response. the most clinically advanced product is a t cell immunostimulatory factor (apc activator), imp321, for cancer chemoimmunotherapy which has completed early phase ii trials. a number of additional lag-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.

Complete history of Frederick Wackerle stock trades at Immutep

Immutep executives and stock owners

Immutep executives and other stock owners filed with the SEC include:

• Marc Voigt,
  CEO, MD, CFO, Chief Bus. Officer & Exec. Director
• Dr. Frederic Triebel M.D., Ph.D.,
  Chief Scientific Officer & Chief Medical Officer
• Deanne Miller LLB,
  COO, Gen. Counsel & Joint Company Sec.
• Shengfei Fang,
  Fin. Director & Assistant Company Sec.
• Christian Mueller,
  Director of Clinical Devel. & Regulatory Affairs
• Indira Naidu,
  Joint Company Sec.
• David Martin Fleet,
  Director
• Donald Francis Sinex,
  Director
• Harvey R Md Colten,
  Director
• Cecilia Chan,
  Executive Vice President
• Gary C Parks,
  Treasurer, Secretary and CFO
• Levi Hong Kaye Lee,
  Director
• Ching Yin Judy Lau,
  Director
• Frederick W Wackerle,
  Director
• Carol Ann Olson,
  VP & Chief Medical Officer
• T Stephen Thompson,
  CEO and President
• Eric L Sorkin,
  Director
• Kon Fung Chan,
  10% owner
• Daniel M Schmitt,
  VP, Licensing & Comm Dev.
• Deborah Zonies,
  VP & General Counsel